MNOV MediciNova, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 13, 2026
$1,78
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$1,1752 haftanın en düşüğü
$3,9052 haftanın en yükseği
Piyasa Değeri (MRQ)
$88M
P/E (TTM)
-8.5
Hisse Başına Kâr (TTM)
$-0.21
Gelir (TTM)
$920.5K
rozetleriniz
52 Haftlık Aralık
$1–$4
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$8
P/E
-8.5
ROE
-25.6%
Net Kâr Marjı
-1168.2%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
MNOV Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$1.78
Piyasa Değeri (MRQ)
$88M
P/E (TTM)
-8.5
Hisse Başına Kâr (TTM)
$-0.21
Gelir (TTM)
$920.5K
ROE (TTM)
-25.6%
52 Haftlık Aralık
$1–$4
MNOV Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$409.7K2021-12-31 → 2025-12-31
Hisse Başına Kâr$-0.242021-12-31 → 2025-12-31
Serbest Nakit Akışı$-10M2016-12-31 → 2025-12-31
Net kar marjı-1168.2%2021-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | MNOV | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -8.55Y ort. ≈-8.6 | ≈-8.6 | · | · | |
| F/S (TTM) | 95.25Y ort. ≈87.8 | ≈87.8 | · | · | |
| F/D (MRQ) | 2.45Y ort. ≈1.5 | ≈1.5 | 1.7 | Adil değer | |
| Fiyat / Serbest Nakit Akışı (TTM) | -9.65Y ort. ≈-9.6 | ≈-9.6 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -9.65Y ort. ≈-9.6 | ≈-9.6 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 2.75Y ort. ≈1.8 | ≈1.8 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | MNOV | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -1287.4%5Y ort. ≈-1495.2% | ≈-1495.2% | -583.5% | En üst düzey | |
| FAVÖK Marjı (TTM) | -1285.3%5Y ort. ≈-1492.6% | ≈-1492.6% | -583.5% | En üst düzey | |
| Pretax Margin (Vergi Öncesi Kar Marjı) | -2927.3%5Y ort. ≈-1345.0% | ≈-1345.0% | -2927.3% | Aynı seviyede | |
| Net Kâr Marjı (TTM) | -1168.2%5Y ort. ≈-1345.6% | ≈-1345.6% | -597.4% | En üst düzey | |
| ROA (TTM) | -23.8%5Y ort. ≈-16.8% | ≈-16.8% | -36.6% | En üst düzey | |
| ROE (TTM) | -25.6%5Y ort. ≈-18.5% | ≈-18.5% | -61.0% | En üst düzey | |
| ROIC | -32.0%5Y ort. ≈-21.0% | ≈-21.0% | -55.9% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | MNOV | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 8.85Y ort. ≈16.3 | ≈16.3 | 5.7 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 8.15Y ort. ≈16.2 | ≈16.2 | 5.3 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | MNOV | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.05Y ort. ≈0.0 | ≈0.0 | 0.0 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$68.3K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
38.0%
Sonraki Rapor
Kas 11, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 11, 2026 | $-0.05 | $-0.06 | 22.6% |
| 31 Mart 2026 | May 14, 2026 | $-0.05 | $-0.07 | 30.0% |
| 31 Aralık 2025 | $-0.05 | $-0.10 | 48.4% | |
| 30 Eylül 2025 | $-0.06 | $-0.10 | 41.2% | |
| 30 Haziran 2025 | $-0.07 | $-0.10 | 27.8% | |
| 31 Mart 2025 | $-0.06 | $-0.14 | 58.0% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $409.7K | · | $1M | · | $4M | · | · | · | · | · | · | · | |
| R&D Expense | $7M | $7M | $5M | $9M | $8M | $7M | $6M | $5M | $4M | $3M | $3M | $3M | |
| SG&A Expense | $6M | $5M | $5M | $5M | $6M | $7M | $8M | $10M | $9M | $7M | $6M | $6M | |
| Operating Expenses | $14M | $13M | $11M | $15M | $14M | $14M | $14M | $16M | $13M | $11M | $9M | $9M | |
| Operating Income | $-13M | $-13M | $-10M | $-15M | $-10M | $-14M | $-14M | $-16M | $-13M | $-11M | $-9M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $298 | $454 | $514 | $628 | |
| Other Non-op | $-12.8K | $-39.5K | $-502.9K | $-247.3K | $-59.5K | $-38.4K | $-46.2K | $-22.9K | $-25.6K | $-47.0K | · | · | |
| Pretax Income | $-12M | $-11M | $-9M | $-14M | $-10M | $-14M | $-13M | $-15M | $-13M | $-11M | $-9M | $-9M | |
| Income Tax | $6.0K | $5.5K | $3.0K | $2.8K | $2.6K | $-1.6K | $12.7K | $5.3K | $-2M | $3.8K | $7.4K | $-4.0K | |
| Net Income | $-12M | $-11M | $-9M | $-14M | $-10M | $-14M | $-13M | $-15M | $-11M | $-11M | $-9M | $-9M | |
| EPS (Basic) | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 | · | · | · | · | · | · | · | |
| Shares (Basic) | 49,063,438 | 49,046,246 | 49,046,246 | 49,045,342 | 48,596,255 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 49,063,438 | 49,046,246 | 49,046,246 | 49,045,342 | 48,596,255 | · | · | · | · | · | · | · | |
| EBITDA | $-13M | $-13M | $-10M | $-15M | $-10M | $-14M | $-14M | $-16M | $-13M | $-11M | $-9M | $-9M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31M | $40M | $51M | $19M | $71M | $60M | $64M | $62M | $28M | $24M | $22M | $12M | |
| Short-term Investments | · | · | · | $40M | · | · | · | · | · | · | · | · | |
| Receivables | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $184.8K | $714.5K | $174.9K | $499.4K | $578.0K | $680.2K | $511.9K | $444.9K | $336.6K | $585.8K | $649.5K | $463.5K | |
| Current Assets | $31M | $41M | $51M | $59M | $72M | $61M | $64M | $63M | $28M | $25M | $23M | $12M | |
| PP&E (Net) | $8.3K | $25.5K | $45.8K | $45.3K | $57.6K | $55.7K | $40.5K | $53.1K | $62.9K | $90.7K | $20.4K | $44.8K | |
| PP&E (Gross) | $431.1K | $428.2K | $489.3K | $478.1K | $482.8K | $579.3K | $538.4K | $536.7K | $534.6K | $590.1K | $503.7K | $506.8K | |
| Accum. Depreciation | $422.8K | $402.7K | $443.5K | $432.8K | $425.2K | $523.6K | $497.9K | $483.5K | $471.7K | $499.4K | $483.2K | $461.9K | |
| Goodwill | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | |
| Other Non-current Assets | $19.0K | $19.0K | $74.2K | $92.8K | $115.5K | $75.4K | $459.8K | $11.0K | $11.0K | · | $109.0K | $10.7K | |
| Total Assets | $46M | $56M | $66M | $74M | $87M | $75M | $79M | $77M | $43M | $40M | $38M | $27M | |
| Accounts Payable | $625.0K | $1M | $1M | $424.6K | $402.7K | $616.6K | $451.3K | $616.8K | $2M | $367.3K | $170.8K | $462.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $2M | $1M | $1M | $1M | $1M | |
| Current Liabilities | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $3M | $2M | $1M | $2M | |
| Capital Leases | $17.1K | $211.5K | $410.7K | $523.6K | $694.7K | $2.7K | $182.6K | · | · | · | · | · | |
| Deferred Tax | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $2M | $2M | $2M | |
| Other Non-current Liabilities | $17.1K | $211.5K | $410.7K | $523.6K | $694.7K | $2.7K | $186.4K | $27.2K | · | · | · | · | |
| Total Liabilities | $4M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | |
| Common Stock | $49.2K | $49.0K | $49.0K | $49.0K | $49.0K | $45.0K | $43.9K | $42.1K | $36.5K | $34.5K | $30.0K | $24.4K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $365M | $352M | $333M | |
| Retained Earnings | $-439M | $-427M | $-416M | $-407M | $-393M | $-383M | $-369M | $-356M | $-341M | $-330M | $-319M | $-311M | |
| AOCI | $-127.2K | $-135.2K | $-118.1K | $-115.3K | $-98.9K | $-88.2K | $-92.7K | $-93.2K | $-94.6K | $-96.0K | $-102.8K | $-101.0K | |
| Stockholders' Equity | $42M | $53M | $62M | $70M | $84M | $71M | $75M | $73M | $39M | $35M | $33M | $22M | |
| Liabilities + Equity | $46M | $56M | $66M | $74M | $87M | $75M | $79M | $77M | $43M | $40M | $38M | $27M | |
| Shares Outstanding | 49,221,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,043,246 | 45,024,560 | 43,908,065 | 42,081,306 | 36,452,893 | 34,523,678 | 29,956,495 | 24,436,317 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $20.1K | $21.1K | $20.3K | $17.7K | $26.1K | $21.3K | $23.9K | $25.9K | $28.1K | $14.1K | $26.7K | $40.2K | |
| Stock-based Comp | $829.1K | $1M | $710.7K | $642.5K | $2M | $3M | $4M | $6M | $4M | $4M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | · | $-2M | · | · | $0 | |
| Other Non-cash | $1M | $-806.2K | $409.5K | $497.3K | $-991.0K | $-169.4K | $-319.9K | $-795.2K | $1M | $333.1K | $-359.5K | $8M | |
| Operating Cash Flow | $-10M | $-11M | $-7M | $-13M | $-9M | $-11M | $-9M | $-9M | $-7M | $-7M | $-7M | $816.5K | |
| CapEx | $2.9K | $895 | $21.3K | $5.0K | $28.7K | $36.5K | $11.3K | $10.2K | · | $84.5K | $2.3K | $3.5K | |
| Investing Cash Flow | $-2.9K | $-697 | $40M | $-40M | $-28.7K | $-36.5K | $-11.3K | $626.3K | · | $-84.5K | · | · | |
| Stock Issued | $244.0K | $0 | · | · | · | · | · | · | · | · | $17M | $4M | |
| Net Stock Activity | $244.0K | · | · | · | · | · | · | · | · | · | $17M | · | |
| Financing Cash Flow | $244.0K | $0 | · | $7.9K | $21M | $7M | $11M | $43M | $11M | $9M | · | · | |
| Net Change in Cash | $-10M | $-11M | $32M | $-53M | $11M | $-4M | $1M | $34M | $4M | $2M | $10M | $5M | |
| Taxes Paid | $6.0K | $5.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-10M | $-11M | $-7M | $-13M | $-9M | $-11M | $-9M | $-9M | · | $-7M | $-7M | $813.0K | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-7M | $-7M | $812.4K |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3242.5% | · | -990.0% | · | -253.0% | · | · | · | · | · | · | · | |
| Net Margin | -2928.8% | · | -857.2% | · | -251.0% | · | · | · | · | · | · | · | |
| Pretax Margin | -2927.3% | · | -856.9% | · | -250.9% | · | · | · | · | · | · | · | |
| EBITDA Margin | -3237.6% | · | -988.0% | · | -252.4% | · | · | · | · | · | · | · | |
| ROA | -23.6% | -18.1% | -12.2% | -17.4% | -12.4% | -17.9% | -16.6% | -24.3% | -26.8% | -28.0% | -27.1% | -32.4% | |
| ROE | -27.1% | -20.5% | -13.5% | -19.6% | -11.9% | -19.1% | -17.3% | -20.0% | -30.5% | -32.3% | -32.3% | -38.8% | |
| ROIC | -32.0% | -24.1% | -15.9% | -20.8% | -12.2% | -19.9% | -18.8% | -21.3% | -29.2% | -31.5% | -27.0% | -41.9% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.2 | 13.9 | 15.6 | 18.5 | 25.4 | 27.7 | 28.9 | 28.6 | 9.8 | 15.2 | 15.2 | 7.6 | |
| Quick Ratio | 8.1 | 13.6 | 15.6 | 18.3 | 25.2 | 27.4 | 28.6 | 28.4 | 9.7 | 14.8 | 14.8 | 7.3 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -43715.1 | -23968.8 | -17164.2 | -14686.3 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | · | 0.0 | · | · | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.84 | $1.07 | $1.27 | $1.43 | $1.71 | $1.58 | $1.71 | $1.74 | $1.06 | $1.00 | $1.09 | $0.90 | |
| Revenue / Share | $0.01 | · | $0.02 | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.20 | $-0.22 | $-0.15 | $-0.26 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.63 | $0.82 | $1.04 | $0.38 | $1.46 | $1.33 | $1.45 | $1.48 | $0.77 | $0.70 | $0.74 | $0.48 | |
| EPS (TTM) | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $409.7K | · | $1M | · | $4M | · | · | · | · | · | · | · | |
| Net Income TTM | $-12M | $-11M | $-9M | $-14M | $-10M | $-14M | $-13M | $-15M | $-11M | $-11M | $-9M | $-9M | |
| Market Cap | $64M | $103M | $74M | $101M | $131M | $237M | $296M | $344M | $236M | $208M | $106M | $74M | |
| P/E | -5.5 | -9.1 | -8.8 | -7.1 | -12.8 | -21.9 | -28.1 | -34.0 | -27.0 | -25.1 | -14.8 | -12.7 | |
| P/S | 157.4 | · | 73.6 | · | 32.6 | · | · | · | · | · | · | · | |
| P/B | 1.6 | 2.0 | 1.2 | 1.4 | 1.6 | 3.3 | 4.0 | 4.7 | 6.1 | 6.0 | 3.2 | 3.4 | |
| P / Tangible Book | 2.0 | 2.4 | 1.4 | 1.7 | 1.8 | 3.8 | · | · | · | · | · | · | |
| P / Cash Flow | -6.6 | -9.7 | -9.9 | -7.8 | -14.0 | -21.9 | -32.4 | -37.7 | -34.1 | -31.8 | -14.9 | 91.0 | |
| P / FCF | -6.6 | -9.7 | -9.9 | -7.8 | -14.0 | -21.8 | -32.4 | -37.7 | · | -31.4 | -14.9 | 91.4 | |
| Earnings Yield | -18.3% | -10.9% | -11.3% | -14.1% | -7.8% | -4.6% | -3.6% | -2.9% | -3.7% | -4.0% | -6.8% | -7.9% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $458.4K | $187.0K | $151.7K | $123.3K | $134.6K | · | · | · | · | · | $0 | $1M | · | · | · | · | |
| R&D Expense | $900.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $700.0K | $2M | $1M | $2M | $2M | |
| SG&A Expense | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $839.3K | $1M | $2M | $1M | $1M | $1M | |
| Operating Expenses | $3M | $3M | $3M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $3M | $3M | $3M | $4M | |
| Operating Income | $-3M | $-3M | $-3M | $-3M | $-4M | $-3M | $-3M | $-3M | $-3M | $-3M | $-2M | $-1M | $-3M | $-3M | $-3M | $-4M | |
| Other Non-op | $-4.9K | $-3.4K | $-5.8K | $-10.2K | $952 | $2.3K | $-15.5K | $9.1K | $-17.1K | $-16.0K | $-2.2K | $-14.2K | $-23.2K | $-463.3K | $-194.7K | $-8.5K | |
| Net Income | $-2M | $-3M | $-3M | $-3M | $-3M | $-3M | $-3M | $-3M | $-3M | $-3M | $-2M | $-723.1K | $-3M | $-3M | $-3M | $-4M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.06 | $-0.06 | $-0.06 | $-0.05 | $-0.06 | $-0.04 | $-0.01 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.06 | $-0.06 | $-0.06 | $-0.05 | $-0.06 | $-0.04 | $-0.01 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | |
| Shares (Basic) | 49,221,246 | 49,221,246 | · | 49,046,246 | 49,046,246 | 49,046,246 | · | 49,046,246 | 49,046,246 | 49,046,246 | · | 49,046,246 | 49,046,246 | 49,046,246 | · | 49,046,246 | |
| Shares (Diluted) | 49,221,246 | 49,221,246 | · | 49,046,246 | 49,046,246 | 49,046,246 | · | 49,046,246 | 49,046,246 | 49,046,246 | · | 49,046,246 | 49,046,246 | 49,046,246 | · | 49,046,246 | |
| EBITDA | $-3M | $-3M | · | $-3M | $-4M | $-3M | · | $-3M | $-3M | $-3M | · | $-1M | $-3M | $-3M | · | $-4M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25M | $27M | $31M | $33M | $34M | $37M | $40M | $42M | $44M | $47M | $51M | $52M | $53M | $55M | $19M | $53M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $40M | · | |
| Receivables | $0 | $245.1K | · | $0 | $134.6K | · | · | · | · | · | · | $1M | · | · | · | · | |
| Prepaid Expense | $505.5K | $571.5K | $184.8K | $359.9K | $729.6K | $1M | $714.5K | $984.9K | $1M | $724.8K | $174.9K | $488.8K | $645.5K | $775.0K | $499.4K | $641.7K | |
| Current Assets | $26M | $28M | $31M | $33M | $35M | $38M | $41M | $43M | $46M | $48M | $51M | $53M | $54M | $56M | $59M | $53M | |
| PP&E (Net) | $9.8K | $14.9K | $8.3K | $12.9K | $15.4K | $20.4K | $25.5K | $30.8K | $35.8K | $40.4K | $45.8K | $51.2K | $54.6K | $41.1K | $45.3K | $45.9K | |
| PP&E (Gross) | · | · | $431.1K | · | · | · | $428.2K | · | · | · | $489.3K | · | · | · | $478.1K | · | |
| Accum. Depreciation | · | · | $422.8K | · | · | · | $402.7K | · | · | · | $443.5K | · | · | · | $432.8K | · | |
| Goodwill | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | |
| Other Non-current Assets | $0 | $0 | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $70.4K | $74.2K | $71.1K | $72.8K | $77.5K | $92.8K | $101.7K | |
| Total Assets | $40M | $43M | $46M | $48M | $50M | $52M | $56M | $58M | $60M | $63M | $66M | $68M | $69M | $71M | $74M | $78M | |
| Accounts Payable | $950.5K | $852.4K | $625.0K | $746.0K | $569.4K | $718.9K | $1M | $708.2K | $667.7K | $804.8K | $1M | $736.9K | $548.2K | $585.1K | $424.6K | $552.7K | |
| Current Liabilities | $3M | $3M | $4M | $3M | $3M | $2M | $3M | $3M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | |
| Capital Leases | $0 | $0 | $17.1K | $74.4K | $117.0K | $165.2K | $211.5K | $255.2K | $302.5K | $351.2K | $410.7K | $463.8K | $519.7K | $489.4K | $523.6K | $555.8K | |
| Deferred Tax | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | $201.8K | |
| Other Non-current Liabilities | $0 | $0 | $17.1K | $74.4K | $117.0K | $165.2K | $211.5K | $255.2K | $302.5K | $351.2K | $410.7K | $463.8K | $519.7K | $489.4K | $523.6K | $555.8K | |
| Total Liabilities | $3M | $3M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $5M | |
| Common Stock | $49.2K | $49.2K | $49.2K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | |
| Retained Earnings | $-444M | $-441M | $-439M | $-436M | $-433M | $-430M | $-427M | $-424M | $-421M | $-418M | $-416M | $-414M | $-413M | $-410M | $-407M | $-404M | |
| AOCI | $-127.4K | $-128.1K | $-127.2K | $-126.8K | $-127.4K | $-130.1K | $-135.2K | $-123.8K | $-131.5K | $-127.0K | $-118.1K | $-123.8K | $-121.0K | $-116.8K | $-115.3K | $-124.3K | |
| Stockholders' Equity | $37M | $39M | $42M | $44M | $47M | $50M | $53M | $55M | $57M | $60M | $62M | $65M | $65M | $68M | $70M | $73M | |
| Liabilities + Equity | $40M | $43M | $46M | $48M | $50M | $52M | $56M | $58M | $60M | $63M | $66M | $68M | $69M | $71M | $74M | $78M | |
| Shares Outstanding | 49,221,246 | 49,221,246 | 49,221,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 | 49,046,246 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $5.0K | $4.3K | $4.6K | $5.3K | $5.1K | $5.2K | $5.2K | $5.2K | $5.4K | $5.3K | $5.5K | $5.7K | $5.0K | $4.1K | $4.3K | $4.5K | |
| Stock-based Comp | $176.8K | $407.8K | $180.6K | $157.7K | $204.9K | $285.9K | $264.0K | $504.9K | $207.5K | $215.4K | $-237.4K | $219.1K | $325.7K | $403.3K | $128.7K | $158.3K | |
| Other Non-cash | · | $-1M | · | · | · | $-1M | · | · | · | $-1M | · | · | · | $-667.3K | · | · | |
| Operating Cash Flow | $-2M | $-3M | $-2M | $-2M | $-2M | $-4M | $-2M | $-2M | $-3M | $-4M | $-499.1K | $-1M | $-2M | $-3M | $-4M | $-3M | |
| CapEx | $0 | $10.8K | $0 | $2.9K | $0 | $0 | $-2 | $6 | · | · | $-22 | $2.7K | · | · | · | · | |
| Investing Cash Flow | $0 | $-10.8K | $0 | $-2.9K | $0 | $0 | $1 | $193 | · | · | $22 | $-2.7K | $-18.6K | $40M | $-30M | · | |
| Financing Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Net Change in Cash | $-2M | $-3M | $-2M | $-2M | $-2M | $-4M | $-2M | $-2M | $-3M | $-4M | $-507.9K | $-1M | $-2M | $37M | $-34M | $-13M | |
| Free Cash Flow | · | $-3M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -554.3% | -1516.6% | · | -2741.7% | -2679.9% | · | · | · | · | · | · | -114.7% | · | · | · | · | |
| Net Margin | -504.8% | -1383.1% | · | -2473.6% | -2437.8% | · | · | · | · | · | · | -72.3% | · | · | · | · | |
| EBITDA Margin | -554.3% | -1514.3% | · | -2741.7% | -2679.9% | · | · | · | · | · | · | -114.7% | · | · | · | · | |
| ROA | -5.1% | -5.4% | · | -5.8% | -5.9% | -5.0% | · | -4.5% | -3.7% | -4.2% | · | -0.99% | · | -3.8% | · | -4.3% | |
| ROE | -5.5% | -5.8% | · | -6.2% | -6.3% | -5.2% | · | -4.8% | -3.9% | -4.4% | · | -1.1% | · | -3.9% | · | -4.6% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.8 | 9.1 | · | 9.9 | 13.3 | 17.7 | · | 16.7 | 18.2 | 19.1 | · | 18.9 | · | 20.6 | · | 11.7 | |
| Quick Ratio | 8.6 | 8.9 | · | 9.8 | 13.0 | 17.1 | · | 16.3 | 17.8 | 18.8 | · | 18.7 | · | 20.4 | · | 11.6 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | · | · | · | 0.0 | · | · | · | · | |
| Receivables Turnover | 6.8 | 0.1 | · | 0.2 | 2.0 | · | · | · | · | · | · | 2.0 | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.76 | $0.80 | · | $0.90 | $0.96 | $1.02 | · | $1.12 | $1.17 | $1.22 | · | $1.32 | · | $1.38 | · | $1.49 | |
| Revenue / Share | $0.01 | $0.00 | · | $0.00 | $0.00 | · | · | · | · | · | · | $0.02 | · | · | · | · | |
| Cash Flow / Share | · | $-0.07 | · | · | · | $-0.08 | · | · | · | $-0.08 | · | · | · | $-0.06 | · | · | |
| Cash / Share | $0.52 | $0.56 | · | $0.66 | $0.70 | $0.75 | · | $0.86 | $0.90 | $0.96 | · | $1.05 | · | $1.13 | · | $1.07 | |
| EPS (TTM) | $-0.21 | $-0.23 | · | $-0.25 | $-0.25 | $-0.23 | · | $-0.21 | $-0.16 | $-0.17 | · | $-0.20 | $-0.26 | $-0.28 | · | $-0.26 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $920.5K | $596.6K | · | · | · | · | · | · | · | · | · | · | $4M | $4M | · | $4M | |
| Net Income TTM | $-11M | $-12M | · | $-12M | $-12M | $-11M | · | $-10M | $-8M | $-8M | · | $-10M | $-12M | $-14M | · | $-13M | |
| Market Cap | $65M | $67M | · | $62M | $64M | $72M | · | $103M | $71M | $71M | · | $103M | · | $106M | · | $106M | |
| P/E | -6.3 | -6.0 | · | -5.1 | -5.2 | -6.3 | · | -10.0 | -9.0 | -8.5 | · | -10.4 | -8.8 | -7.7 | · | -8.3 | |
| P/S | 70.6 | 113.0 | · | · | · | · | · | · | · | · | · | · | 27.9 | 26.2 | · | 26.4 | |
| P/B | 1.7 | 1.7 | · | 1.4 | 1.4 | 1.4 | · | 1.9 | 1.2 | 1.2 | · | 1.6 | · | 1.6 | · | 1.5 | |
| P / Tangible Book | 2.3 | 2.3 | · | 1.8 | 1.7 | 1.8 | · | 2.3 | 1.5 | 1.4 | · | 1.9 | · | 1.8 | · | 1.7 | |
| P / Cash Flow | · | -19.4 | · | · | · | -18.9 | · | · | · | -18.4 | · | · | · | -33.3 | · | · | |
| Earnings Yield | -15.9% | -16.8% | · | -19.7% | -19.1% | -15.8% | · | -10.0% | -11.1% | -11.7% | · | -9.6% | -11.3% | -13.0% | · | -12.0% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $409.7K | · | $1M | · | $4M |
| Faaliyet Kâr Marjı % | -3242.5% | · | -990.0% | · | -253.0% |
| Net Gelir | $-12M | $-11M | $-9M | $-14M | $-10M |
| Seyreltilmiş Hisse Başı Kâr | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 8.2 | 13.9 | 15.6 | 18.5 | 25.4 |
| Cari Oran | 8.1 | 13.6 | 15.6 | 18.3 | 25.2 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-10M | $-11M | $-7M | $-13M | $-9M |
Kurumsal Sahipler (13F) 31 dosya · $7.8M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
31
Tutulan Değer
$7.8M
Yeni pozisyonlar
3
Çıkan pozisyonlar
4
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 3 (-2 önceki Ç'ye göre) | 4 (-1 önceki Ç'ye göre) | 5 (-3 önceki Ç'ye göre) | 8 (-1 önceki Ç'ye göre) | -226K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| Essex Woodlands Management, Inc. | $1.459.842 | 1.105.941 | 18,78% | Hisse senetleri |
| BlackRock, Inc. | $992.760 | 752.091 | 12,77% | Hisse senetleri |
| VANGUARD GROUP INC | $924.369 | 705.625 | 11,89% | Hisse senetleri |
| CITIGROUP INC | $839.144 | 635.715 | 10,80% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $803.949 | 609.052 | 10,34% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $712.087 | 539.312 | 9,16% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $373.043 | 282.608 | 4,80% | Hisse senetleri |
| UBS Group AG | $293.304 | 222.200 | 3,77% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $271.128 | 205.400 | 3,49% | Hisse senetleri |
| STATE STREET CORP | $255.681 | 193.698 | 3,29% | Hisse senetleri |
| NORTHERN TRUST CORP | $189.638 | 143.665 | 2,44% | Hisse senetleri |
| Bank of New York Mellon Corp | $103.325 | 78.277 | 1,33% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $94.388 | 71.506 | 1,21% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $73.961 | 56.031 | 0,95% | Hisse senetleri |
| SBI Securities Co., Ltd. | $67.952 | 51.479 | 0,87% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $66.728 | 50.552 | 0,86% | Hisse senetleri |
| BARCLAYS PLC | $56.504 | 42.806 | 0,73% | Hisse senetleri |
| Schonfeld Strategic Advisors LLC | $47.726 | 36.157 | 0,61% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $35.313 | 26.752 | 0,45% | Hisse senetleri |
| JANE STREET GROUP, LLC | $20.880 | 15.818 | 0,27% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $20.591 | 15.599 | 0,26% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $17.854 | 13.526 | 0,23% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $17.685 | 13.500 | 0,23% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $17.370 | 13.159 | 0,22% | Hisse senetleri |
| Focus Partners Advisor Solutions, LLC | $13.200 | 10.000 | 0,17% | Hisse senetleri |
| MORGAN STANLEY | $2.640 | 2.000 | 0,03% | Hisse senetleri |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $403 | 305 | 0,01% | Hisse senetleri |
| OSAIC HOLDINGS, INC. | $87 | 66 | 0,00% | Hisse senetleri |
| Larson Financial Group LLC | $7 | 5 | 0,00% | Hisse senetleri |
| HANTZ FINANCIAL SERVICES, INC. | $6 | 4.232 | 0,00% | Hisse senetleri |
| Caitong International Asset Management Co., Ltd | $3 | 2 | 0,00% | Hisse senetleri |
Aktivistler ve %5+ sahipler 4 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| 3D Investment Partners Pte. Ltd., 3D Opportunity Master Fund ×3 başvurular | 29 Eylül 2026 | 9,90% | Değişiklik | · | SEC |
| KISSEI PHARMACEUTICAL CO., LTD ×3 başvurular | 14 Haziran 2017 | · | İlk başvuru | Pasif yatırım | SEC |
| Essex Woodlands Health Ventures Fund VI, L.P., Essex Woodlands Health Ventures VI, L.P., Essex Woodlands Health Ventures VI, L.L.C., James L. Currie, Martin P. Sutter, Immanuel Thangaraj, Jeff Himawan, Ph.D, Petri Vainio, MD, Ph.D. ×2 başvurular | 12 Şubat 2016 | · | İlk başvuru | · | SEC |
| Yuichi Iwaki | 28 Ocak 2011 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 27 içeriden öğrenenler · 13 yöneticiler · 12 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Yuichi Iwaki | President and CEO | 16 Ocak 2026 A | 966.933 | 0 | 0 | $0 |
| Esther Van Den Boom | Chief Financial Officer | 07 Ağustos 2014 A | · | 0 | 0 | $0 |
| Shintaro Asako | Chief Financial Officer | 29 Ocak 2010 A | · | 0 | 0 | $0 |
| Kazuko Matsuda | Chief Medical Officer | 16 Ocak 2026 A | 322.996 | 0 | 0 | $0 |
| Geoffrey Obrien | Vice President | 09 Ocak 2024 A | 48.318 | 0 | 0 | $0 |
| Federico C.A. Gaeta | Chief Scientific Officer | 22 Nisan 2021 A | · | 0 | 0 | $0 |
| Masatsune Okajima | VP and Head of Japanese Office | 28 Şubat 2019 M | 1.040.530 | 0 | 0 | $0 |
| Michael Denis Coffee | Chief Business Officer | 13 Mayıs 2013 A | 4.000 | 0 | 0 | $0 |
| Kirk William Johnson | Chief Scientific Officer | 13 Mayıs 2013 A | 1.700 | 0 | 0 | $0 |
| Michael E Kalafer | Chief Medical Officer | 28 Temmuz 2009 X | 31.744 | 0 | 0 | $0 |
| Richard E Gammans SR | Chief Development Officer | 30 Ocak 2009 A | · | 0 | 0 | $0 |
| Kenneth W Locke | Chief Scientific Officer | 07 Ocak 2008 A | · | 0 | 0 | $0 |
| Joji Suzuji | Sr. V.P., Finance & Admin. | 04 Ocak 2006 A | · | 0 | 0 | $0 |
| Nicole Lemerond | Yönetim kurulu üyesi | 23 Haziran 2026 A | · | 0 | 0 | $0 |
| Carolyn Beaver | Yönetim kurulu üyesi | 23 Haziran 2026 A | · | 0 | 0 | $0 |
| Hideki Nagao | Yönetim kurulu üyesi | 23 Haziran 2026 A | 0 | 0 | 0 | $0 |
| Yutaka Kobayashi | Yönetim kurulu üyesi | 16 Haziran 2020 A | 25.000 | 0 | 0 | $0 |
| Yoshio Ishizaka | Yönetim kurulu üyesi | 10 Haziran 2019 A | 10.000 | 0 | 0 | $0 |
| Tatsuo Izumi | Yönetim kurulu üyesi | 12 Aralık 2013 S | 600.000 | 0 | 0 | $0 |
| Arlene Morris | Yönetim kurulu üyesi | 21 Mayıs 2013 M | 0 | 0 | 0 | $0 |
| David D O'Toole | Yönetim kurulu üyesi | 29 Mayıs 2012 P | 5.000 | 0 | 0 | $0 |
| Hiroaki Shigeta | Yönetim kurulu üyesi | 10 Mayıs 2012 M | 45.000 | 0 | 0 | $0 |
| John K A Prendergast | Yönetim kurulu üyesi | 18 Temmuz 2011 A | · | 0 | 0 | $0 |
| Jeff Himawan | Yönetim kurulu üyesi | 14 Haziran 2011 A | · | 0 | 0 | $0 |
| Alan W Dunton | Yönetim kurulu üyesi | 11 Haziran 2010 A | · | 0 | 0 | $0 |
| Daniel Vapnek | · | 09 Haziran 2008 A | · | 0 | 0 | $0 |
| Tanabe Holding America Inc. | · | 13 Ekim 2006 D | 5.000.000 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 2 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
MNOV Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 9 analist
AL
Medyan hedef
$8.00
+349,4%
2 22,2%
Güçlü Al
6 66,7%
Al
1 11,1%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
4 analist · 2026-09-27Ortalama hedef $8.25 +363,5%
← Tüm hedeflerin altında
Mevcut fiyat $1.78
Düşük$6.00
Ortalama$8.25
Yüksek$11.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| MNOV | $64M | -5.5 | · | -2928.8% | -27.1% | · |
| ATRA | $132M | 7.0 | -6.3% | 27.1% | -88.9% | · |
| BMEA | $90M | -1.1 | -67.1% | -3326.0% | -216.6% | · |
| RLYB | $4M | -0.4 | 34.9% | -1046.4% | -17.3% | · |
| ICCC | · | -51.2 | 4.3% | · | · | · |
| CTOR | $170M | -6.0 | · | · | -61.5% | · |
| CNXU | · | · | · | · | · | · |
| EQ | $95M | -4.0 | 13.9% | · | -133.1% | · |
| CRDF | $192M | -4.1 | -13.2% | -7732.0% | -88.2% | · |
| ACRV | $76M | -1.2 | · | · | -61.0% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 13, 2026